Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | HPGD | P15428 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193133 | 0.94 | TDP1 (0.39) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL30276268 | 0.85 | TDP1 (0.48) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL30887566 | 0.83 | CA12 (0.48) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL30205792 | 0.82 | KDM4E (0.58) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL30607050 | 0.81 | TDP1 (0.49) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL17312337 | 0.81 | TDP1 (0.49) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL29543547 | 0.81 | TDP1 (0.44) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL15571611 | 0.81 | TDP1 (0.44) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL2967595 | 0.80 | RAB9A (0.52) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL29544088 | 0.80 | CA12 (0.49) | TDP1CA12CA1CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3589743-B1 | RECOVERY MEDIUM FOR DETECTION OF MICROORGANISMS BY FLUORESCENCE | AMERICAN STERILIZER CO (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022006232-A2 | DRUG REPURPOSING FOR TREATMENT OF VIRAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210171576-A1 | METHODS FOR TREATING CANCER WITH ACYLDEPSIPEPTIDE ANALOGS | HOURY WALID A (CA) | 2021-06-10 | — | — | US | disclosed |
| US-10301631-B2 | Biological indicator | AMERICAN STERILIZER COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180273957-A1 | BIOLOGICAL INDICATOR | AMERICAN STERILIZER CO (US) | 2018-09-27 | — | — | US | disclosed |
| WO-2018160449-A1 | RECOVERY MEDIUM FOR DETECTION OF MICROORGANISMS BY FLUORESCENCE | AMERICAN STERILIZER COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180245122-A1 | RECOVERY MEDIUM FOR DETECTION OF MICROORGANISMS BY FLUORESCENCE | AMERICAN STERILIZER COMPANY | 2018-08-30 | — | — | US | disclosed |
| EP-2970992-B1 | STERILIZATION INDICATOR INCLUDING A SIMPLIFIED GENETICALLY ENGINEERED BIOLOGICAL INDICATOR | AMERICAN STERILIZER CO (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10017772-B2 | Biological indicator | AMERICAN STERILIZER COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| US-10011843-B2 | Biological indicator | AMERICAN STERILIZER COMPANY (US) | 2018-07-03 | — | — | US | disclosed |
| US-20080070231-A1 | Reporter genes taken up by microorganism, and repressor gene inhibits expression | AMERICAN STERILIZER COMPANY | 2008-03-20 | — | — | US | disclosed |
| US-20060142171-A1 | Novel alkaline protease | FORSKARPATENT I SYD AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060127385-A1 | Method for sustaining enos activity | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 2006-06-15 | — | — | US | disclosed |
| EP-1611235-A1 | NOVEL ALKALINE PROTEASE | Forskarpatent i Syd AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085639-A9 | NOVEL ALKALINE PROTEASE | FORSKARPATENT I SYD AB (SE) | 2005-11-10 | — | — | WO | disclosed |
| WO-2004085639-A1 | NOVEL ALKALINE PROTEASE | FORSKARPATENT I SYD AB (SE) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004052364-A1 | METHODS FOR SUSTAINING eNOS ACTIVITY | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6448245-B1 | CONTACTING THE CALPAIN WITH AN EFFECTIVE AMOUNT OF AN HIV PROTEASE INHIBITOR, | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-09-10 | — | — | US | disclosed |
| US-20020115665-A1 | METHODS OF AND COMPOUNDS FOR INHIBITING CALPAINS | THE GOVERNMENT OF THE USA, AS REPRESENTED BY TH SECRETARY, DEPARTMENT | 2002-08-22 | — | — | US | disclosed |
| WO-2001082919-A2 | METHODS OF AND COMPOUNDS FOR INHIBITING CALPAINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115665-A1 | METHODS OF AND COMPOUNDS FOR INHIBITING CALPAINS | CAPNS1, CAPN1, CAPN9 | TDP1 548/4885CA12 3086/4885CA1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.